Form S-1
When discussing non-GAAP financial measures, please ensure that such disclosure is accompanied by the corresponding GAAP measure with equal or greater prominence. For example, you refer to positive free cash flow for the last five years, but do not provide a similar reference to the corresponding GAAP measure. Please revise. Refer to Question 102.10 of the Non-GAAP Compliance and Disclosure Interpretations.
On behalf of our client, JFrog Ltd. (“JFrog” or the “Company”), we submit this letter to assist the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in its review of the Company’s Registration Statement on Form S-1 (File No. 333-248271) (the “Registration Statement”). This letter supplements the Company’s responses to comment number 11 received from the Staff by letter dated March 5, 2020 (the “March Response”) and comment number 3 received from the Staff by letter dated August 13, 2020 (the “August Response” and, together with the March Response, the “Prior Responses”), each relating to the Registration Statement.One letter for all the questions, without numbered answers. Read the replyRest of the letter
The Prior Responses set forth a breakdown of all share options granted by the Company in fiscal year 2019 through July 31, 2020 as well as the fair value of the underlying ordinary shares used to value such awards, as determined by the Company’s board of directors (the “Board”). SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE Because of the commercially sensitive nature of information contained herein, this submission is accompanied by the Company’s request for confidential treatment for selected portions of this letter. The Company has filed a separate letter with the Office of Freedom of Information and Privacy Act Operations in connection with the confidential treatment request, pursuant to Rule 83 of the Commission’s Rules on Information and Requests, 17 C.F.R. § 200.83. For the Staff’s reference, we have enclosed a copy of the Company’s letter to the Office of Freedom of Information and Privacy Act Operations, as well as a copy of this correspondence, marked to show the portions redacted from the version filed via EDGAR and for which the Company is requesting confidential treatment. For the convenience of the Staff, we are providing to the Staff by overnight delivery copies of this letter. The Company supplementally advises the Staff that on August 24, 2020 (the “Initial Range Date”), representatives from Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and BofA Securities, Inc., the lead underwriters for the Company’s initial public offering (“IPO”), on behalf of the underwriters, formally advised the Company that, based on then-current market conditions, the Company’s financial condition and prospects and recent public offerings of other comparable companies, it anticipated that the underwriters would recommend to the Company a preliminary price range of $[*****] to $[*****] per share (the “Preliminary Price Range”), resulting in a midpoint of the Preliminary Price Range of $[*****] per share (the “Midpoint Price”). Prior to August 24, 2020, the Company had not held formal discussions with the underwriters regarding a preliminary price range. The Preliminary Price Range does not take into account the current lack of liquidity for the Company’s ordinary shares and assumes a successful IPO, with no weighting attributed to any other outcome for the Company’s business, such as remaining a privately-held company, as set forth in the discussion below. The Company advises the Staff that the Preliminary Price Range represents the Company’s belief of what the indicative price range to be disclosed in the preliminary prospectus may be, but that the actual indicative price range to be included in the preliminary prospectus will not be determined until the Company completes a valuation process with the underwriters. This valuation process is expected to occur shortly before the printing of the preliminary prospectus for the commencement of the roadshow for the Company’s IPO. Therefore, the Preliminary Price Range is subject to further change, which may result from various factors including, but not limited to, then-current market conditions and subsequent business, market, and other developments affecting the Company. The indicative price range to be included in the preliminary prospectus, when determined, will be included in an amendment to the Registration Statement prior to distribution of any preliminary prospectus to potential investors. We are providing this information to you supplementally to facilitate the Staff’s review of the Company’s fair value determinations. Historical Fair Value Determination and Methodology As discussed in the Registration Statement and in the Prior Responses, the Company accounts for share-based compensation expense related to share-based awards based on the estimated fair value of the award on the grant date using the Black-Scholes option-pricing model. As described in the Registration Statement, this model requires the input of highly subjective assumptions, including the fair value of the underlying ordinary TREATMENT REQUESTED BY JFROG LTD. PURSUANT TO 17 C.F.R. §200.83 shares. The Prior Responses set forth a breakdown of all equity awards granted by the Company in fiscal year 2019 through July 31, 2020 as well as the fair value of the underlying ordinary shares used to value such awards, as determined by the Board. The Company respectfully refers the Staff to the Prior Responses for a discussion of the determination of the fair market value per share of the Company’s ordinary shares for financial reporting purposes by the Board for fiscal year 2019 through July 31, 2020, including a full description of the valuation methods used, including the probability-weighted expected return method (“PWERM”) and the Public Company Market Multiple Method (“PCMMM”) of the market approach, the application of a discount for lack of marketability (“DLOM”) and the other key considerations of the Board. An updated discussion of the determinations for the July 2020 option grants is set forth below. As previously communicated in the August Response, the Company and a third-party valuation firm performed a valuation of the Company’s ordinary shares as of June 30, 2020, which determined a fair value of $20.61 per ordinary share (the “June 2020 Valuation”). The Company respectfully refers the Staff to the August Letter for a discussion of the determination of the fair market value per share of the Company’s ordinary shares as of June 30, 2020. Company and a third-party valuation firm subsequently performed an updated valuation report dated as of July 29, 2020, which provided for a fair value per share of the Company’s ordinary shares of $23.00. The Company granted options to purchase 1,343,355 ordinary shares on July 29, 2020 with an exercise price of $23.00 per share based on such valuation report (the “July 2020 Grants”). For financial reporting purposes in connection with the IPO process and due to the proximity of the July 2020 Grants to the determination of the Preliminary Price Range, the Company intends to retrospectively assess the fair value of the Company’s ordinary shares in connection with such grants using a straight-line methodology from the June 2020 Valuation through the midpoint of the actual indicative price range disclosed on the cover of the Company’s preliminary prospectus (including any amendments thereto). The Company believes that the straight-line methodology provides the most reasonable basis for the valuation of its ordinary shares because the Company did not identify any single event that occurred during the period between valuation dates that would have caused a material change in fair value at the grant date. Based on the retrospective valuation, the Company will revise the subsequent events footnote in an amendment to its Registration Statement to reflect the aggregate amount of share-based compensation expense for those awards issued after June 30, 2020, which is expected to be recognized over a weighted-average requisite service period of approximately five years. Determination of Preliminary IPO Price Range As noted above, the Preliminary Price Range is $[*****] to $[*****] per share. The Preliminary Price Range was determined based, in large part, on discussions among the senior management of the Company, the Board, and representatives of the lead underwriters that took place on August 24, 2020. In addition, the Preliminary Price Range was derived using a combination of valuation methodologies, including: (a) a comparison of public companies at a similar stage of development; (b) a comparison of valuations for comparable issuers in the Company’s industry at the time of their respective IPOs; and (c) a current analysis of the public equity market by the underwriters for the offering. The primary factors that account for the increase of the Preliminary Price Range relative to the June 30, 2020 estimated fair value are set forth below. The valuation methodology applied to the Preliminary Price Range assumes a successful IPO in September 2020 with no weighting placed on any other outcome of the Company, such as an acquisition or remaining private prior to undergoing a liquidity event at a later date. Therefore, the Preliminary Price Range effectively weighs a near-term IPO outcome at 100%. In addition, it assumes that a public market for the Company’s ordinary shares has been created, thereby excluding a DLOM inherent in the Company’s ordinary shares. In contrast, the June 2020 Valuation Report considered three scenarios — (1) an IPO on/around [*****] with a probability of [*****], (2) an IPO on/around [*****], with a probability of [*****], and (3) remaining a private company prior to undergoing a liquidity event on/around June 2022, with a probability of [*****]. Both IPO scenarios derived an estimate of the Company’s equity value upon IPO based on the PCMMM of the market approach and Company management’s expectations regarding IPO values at the expected timeframes. The remaining a private company scenario derived an estimate of the Company’s equity value using a combination of the PCMMM and the income approach. Other key assumptions used in the PWERM were a discount rate of 14.5% applied to all three scenarios, and the application of a DLOM of 10.0%, 20.0%, and 27.5% applied to scenarios (1), (2), and (3), respectively. Further, the June 2020 Valuation Report utilized a quantitative methodology to determine the fair value of the Company’s ordinary shares, which may differ from the more qualitative and subjective methodology used by some public market investors to determine the price they are willing to pay in an IPO. Further, the holders of the Company’s convertible preferred shares currently enjoy substantial economic rights and preferences over the holders of ordinary shares, including the right to receive both liquidation payments in preference to holders of ordinary shares and dividends, if declared, prior to any dividends declared or paid on any shares of the Company’s ordinary shares. The Preliminary Price Range assumes the conversion of all of the Company’s convertible preferred shares into ordinary shares immediately prior to the completion of the IPO. The corresponding elimination of the preferences and rights enjoyed by the holders of such convertible preferred shares results in a higher valuation for the ordinary shares. Lastly, given the proximity to the completion of the IPO, the Preliminary Price Range assumes a successful IPO, which would provide the Company with proceeds that substantially strengthen the Company’s balance sheet, as well as provide the Company with access to the U.S. public company equity and debt markets. Market Conditions valuation considerations for estimating the Preliminary Price Range were informed by current conditions in the U.S. equity markets, which are currently trading at near-record levels, despite recent volatility due to the impact of the COVID-19 pandemic, political uncertainty in advance of the November 2020 U.S. elections, corporate earnings, Federal Reserve rate pronouncements, and global trade debates. For example, the Nasdaq Composite index improved by 13% from June 30, 2020 to August 24, 2020. In addition, a significant number of technology companies have either completed IPOs or made public filings related to expected IPOs. Further, software IPOs in the past month have experienced significant first day price increases. On August 5, 2020, BigCommerce Holdings stock increased 201.1% from its offer price in its first day of trading. On August 14, 2020, Duck Creek Technologies stock increased 48.1% from its offer price in its first day of trading. These market trends suggest a potentially favorable market for companies similar to the Company in executing and completing IPOs. As detailed in the Registration Statement and based on the above analysis, the Company respectfully submits to the Staff that it has fully complied with the applicable rules and regulations for the determination of fair value, including the best practices outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The Company advises the Staff that the Company intends to use the midpoint of the indicative price range disclosed on the cover of the Company’s preliminary prospectus to value for financial reporting purposes any additional equity awards granted after the Initial Range Date until the time that there is a public market for its ordinary shares. Please indicate receipt of this request for confidential treatment by date stamping the enclosed copy of the first page of this letter and returning it in the envelope provided.
You disclose that 20 of the top 25 financial services organizations, 9 out of the top 10 technology organizations, and 8 out of the 10 retail organizations in the Fortune 500 have adopted JFrog. Please provide further context regarding the nature of these relationships and explain whether these customers together represent a material portion of your revenue or are among the customers that had ARR of at least $1.0Rest of the question
million as of December 31, 2019.
See the reply above.
You calculate your current market opportunity to be approximately $22 billion based on estimates of the total number of organizations globally. Given that the company generates revenue primarily from the United States and Israel, please disclose the material assumptions and limitations of calculating your market opportunity based on all organizations in all industries globally.
See the reply above.
Please define your references to customers and clarify whether they include only paying customers or also users of your free, freemium and open source offerings.
See the reply above.
You state that free access helps generate demand for your paid offerings and users of your free trials, freemium offerings and open source software options provide low-friction points of entry for prospective customers who often upgrade to paid and higher-tiered subscriptions.Rest of the question
Please tell us whether you use any metrics to monitor the extent to which you are able to convert free access users to paying customers, and if so, provide quantitative disclosure of such metrics for the periods presented. Refer to Item 303(a)(3) of Regulation S-K and Section III.B.1 of SEC Release 33-8350.
See the reply above.
We note that your net dollar and gross dollar retention rate measures are based on annual recurring revenue (ARR) for a set of customers. Please clarify whether ARR for these calculations is the same as for the cohort analysis discussed on page 68 or revise to explain how you determine ARR for these measures.Rest of the question
Tell us whether ARR includes monthly subscription arrangements and, if so, explain your basis for annualizing revenue derived from monthly customers. Lastly, with regards to the gross dollar retention rate amounts that you intend to provide, please ensure that you include the actual amount as of both December 31, 2018 and 2019 separately rather than stating such amounts were above a certain percentage.
See the reply above.
Please disclose the number of customers with an ARR of at least $1.0 million as of December 31, 2018.
See the reply above.
You disclose that revenues from SaaS arrangements are recognized based on usage as the usage occurs over the contract period. Please clarify the billing and timing of revenue recognition for your SaaS subscriptions with minimum annual usage commitments. In your response, tell us the amount of revenues related to such arrangements. Refer to paragraphs 50-9 and 50-12 of ASC 606-10-50.
See the reply above.
You disclose that subscriptions are offered on either an annual or monthly term. Please describe the reasons for the significant non-current deferred revenue balance. Refer to ASC 606-10-50-9.
See the reply above.
On page 21 you state that certain of your self-managed products are sold with perpetual licenses. Please tell us whether you also offer term licenses for self-managed products. If so, tell us the amount of revenue recognized related to term licenses and the related subscriptions for each period presented.Rest of the question
Also, describe your determination for the allocation of transaction price between the license and the support and maintenance contracts and provide us with the percentage allocation for each. Refer ASC 606-10-3231 through 32-25.
See the reply above.
Please disclose any share-based issuances subsequent to the most recent balance sheet date and the expected financial statement impact, if material. As part of your response, provide us with a breakdown of all stock options granted during fiscal 2019 and to date in fiscal 2020 and include the fair value of the underlying ordinary shares used to value such awards.Rest of the question
To the extent there were any significant fluctuations in the fair values from period-to-period, please describe for us the factors that contributed to these fluctuations, including any intervening events within the company or changes in your valuation assumptions or methodology. Refer to ASC 855-10-50-2.
See the reply above.
Please disclose the source of the following assertions in your prospectus: • You provide a leading CRM platform (pages 1, 63 and 84); and • You pioneered a new, systematic, and automated approach to package management (page 90).
See the reply above.
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
See the reply above.
We note your response to prior comment 2. Please disclose the extent to which the customers identified in the prospectus summary collectively constituted a material portion of your revenue for the year ended December 31, 2019.
No reply letter found.
We note the various revisions made in response to prior comment 1. Please further revise to include operating cash flow information in your Summary Consolidated Financial Data table to avoid placing undue prominence to the non-GAAP measure of free cash flow. Similar revisions should be made to your Selected Consolidated Financial Data table.Rest of the question
Refer to Question 102.10 of the Non-GAAP Compliance and Disclosure Interpretations.
No reply letter found.
In response to prior comment 8 you state that customers typically consume substantially all of their contractual minimum usage commitment by the end of their contract period. Please clarify for us whether there is general consistency in the pattern of revenue recognition throughout the contract period for these arrangements.Rest of the question
Describe the frequency with which customers exceed the minimum commitment prior to the end of contract period and tell us what, if any, impact this may have on your results of operations in any given period.
No reply letter found.
We note your response to prior comment 10. Please describe for us the nature of the services provided with your technical support and whether such services vary by product. Also, expand your disclosure in the forepart of your document to include a more comprehensive discussion of such services. Lastly, tell us the percentage of arrangements that include technical support services.
No reply letter found.
We note you present the line item "Preferred enterprise and foreign tax rate differential" in your tax rate reconciliation. Please tell us the individual impact of Preferred enterprise status and the foreign tax rate differential on your tax expense and rate reconciliation for each period presented and present these as separate line items on your reconciliation, as applicable.Rest of the question
Refer to Rule 4-08(h)(2) of Regulation S-X and ASC 74010-50-12.
No reply letter found.
It appears that the company may meet the definition of an Investment Company under the 40% test outlined in Section 3(a)(1)(C) of the Investment Company Act of 1940. Please provide an analysis as to why the company should not be considered an Investment Company under Section 3.
No reply letter found.
We note your response to prior comment 6 that you maintain interests in sovereign debt. Please provide more information on what the sovereign debt investments are and address whether they are “capital preservation instruments” under Rule 3a-8(a)(4).
No reply letter found.
We note your representation that you will pass a board resolution pursuant to Rule 3a8(a)(6)(iv) in July 2020 stating that you are primarily engaged in a business other than investing, reinvesting, owning, holding, or trading in securities. Please confirm that you understand that you will not be able to rely on Rule 3a-8 until this resolution is adopted.
No reply letter found.
You state that Net New ARR began to decelerate in March 2020 after strong year-overyear growth in January and February. In an effort to add context to the impact of COVID19 on your business, please also provide these measures for the comparable periods in fiscal 2019.
to the Staff’s comment, the Company has revised the disclosure on page 67 of the Registration Statement regarding the impact of the COVID-19 pandemic on the Company’s business to include additional disclosure regarding the Company’s net dollar retention rate for the second quarter of 2020, both on a standalone quarterly basis and on a trailing four quarter basis, to provide additional detail on expected future growth.Read in the replyRest of the answer
In addition, the Company has revised the disclosure regarding the year-over-year growth of total ARR for the first and second quarters of 2020 to include the year-over-year growth rates for the first and second quarters of 2019 for historical comparison to clearly illustrate the impact of the decline in growth primarily due to COVID-19, as well as additional narrative disclosure regarding new ARR from existing and new customers during the second quarter of 2020.
The Company respectfully advises the Staff that management does not consider quarterly net new ARR to be sufficiently consistent over historical periods to be meaningful in evaluating the impact of the COVID-19 pandemic on the Company’s business. The
Company’s net new ARR fluctuated in the past irrespective of the COVID -19 impact. Therefore, the Company further advises the Staff that it believes the disclosure of its gross dollar retention rate, net dollar retention rate, and its total growth in ARR provides investors with meaningful information regarding the impact of the COVID-19 pandemic on the Company’s business, including the expansion of existing customers and continued growth of the Company during the periods. In addition, the Company believes that the additional disclosure of the net dollar retention rate for the second quarter of 2020 on a standalone basis accurately reflects the impact of COVID-19 on ARR growth and the trailing four quarters net dollar retention rate is the best predictor of future growth. The Company has supplementally provided the Staff with historical data regarding total quarterly ARR and net new ARR under separate cover.
CONFIDENTIAL TREATMENT REQUESTED BY JFROG LTD. PURSUANT TO 17 C.F.R.
Please explain further how an increase in tax on your U.S. operations increased your effective tax rate during the first half of fiscal 2020 to 213%. Also, clarify whether you anticipate this increase to be indicative of an upward trend in your effective tax rate and if so, revise your disclosures as necessary to describe how such trends may impact your future tax expense.Rest of the question
Please refer to Item 303(a)(3) of Regulation S-K and Section III.B.3 of SEC Release No. 33-8350.
to the Staff’s comment, the Company respectfully advises the Staff that its provision for income taxes increased byRead in the reply
$0.1 million for the six months ended June 30, 2020 compared to the six months ended June 30, 2019. The increase in the provision for income taxes was due to an increase in taxable income from the Company’s operations in the
United States, primarily as a result of higher non-deductible share-based compensation.
The
Company’s effective tax rate is mainly affected by non-deductible share-based compensation expense in the United States and losses before income tax in Israel forRest of the answer
which a full valuation allowance is provided. While the provision for income taxes increased by $0.1 million, the Company’s income (loss) before taxes changed from a loss of $(1.4) million during the six months ended June 30, 2019 to income of $0.4 million for the six months ended June 30, 2020. The change was primarily a result of a decrease in the loss before income taxes in Israel. As no tax benefit related to losses in Israel was recognized due to the full valuation allowance, the tax expense recognized on U.S. operations represented a higher percentage of the total consolidated income before income taxes during the current period. Therefore, the Company’s effective tax rate increased to 213% for the six months ended June 30,
2020 from (52)% of its income (loss) before taxes for the six months ended June 30, 2019.
The Company further advises the Staff that the Company’s future effective tax rate will continue to be impacted by non-deductible expenses, such as share-based compensation, and changes in its valuation allowance in Israel. In addition, the
Company’s future effective tax rate will also be affected by tax rates in foreign jurisdictions and the relative amounts of income it earns in those jurisdictions. The Company does not believe the increase in its effective tax rate in the six months ending June 30, 2020 to be indicative of an upward trend in its future effective tax rates, as the effective tax rate can be affected upward or downward due to the factors mentioned above.
In response to the Staff’s comment, the Company has revised the disclosure on p. 79 of the Registration Statement to provide additional information regarding the increase in provision for income tax for the six months ended June 30, 2020 compared to the six months ended June 30, 2019.
Please provide us with a breakdown of all stock options granted to date in fiscal 2020 and include the fair value of the underlying shares used to value such awards. We refer you to comment 11 in your response letter dated March 26, 2020 where you indicated that you would provide such information once the interim financials are completed and reviewed.Rest of the question
To the extent there were any significant fluctuations in the fair value from period-to-period, please describe for us the factors that contributed to these fluctuations, including any intervening events within the company or changes in your valuation assumptions or methodology. In this regard, it appears that the weighted average exercise price for the grants made subsequent to the most recent balance sheet date was approximately 46% higher than those made during the six months ended June 30, 2020.
to the Staff’s comment, the Company respectfully advises the Staff that the estimate of the fair value per share of the Company’s ordinary shares had been determined at each grant date by the Company’s Board of DirectorsRead in the reply
(“Board”), taking into account contemporaneous third-party valuations reports (“Valuation Reports”) and input from management.Rest of the answer
Such Valuation Reports were performed in accordance with the guidelines outlined in the
American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
In valuing the Company’s ordinary shares, absent an arm’s-length current or recent round of financing, the fair value of the Company’s business, or equity value, was determined using both the income approach and market approach. The income approach estimates value based on the expectation of future cash flows that the Company will generate. These future cash flows are discounted to their present values using a discount rate based on the capital rates of return for comparable publicly traded companies and are adjusted to reflect the risks inherent in the Company’s cash flows relative to those inherent in the companies utilized in the discount rate calculation. The market approach estimates value based on a comparison of the Company to comparable public companies in a similar line of business. From the comparable companies, a representative market multiple is determined and then applied to the Company’s financial results to estimate the value of the Company.
Fair value per share for financial reporting
For financial reporting purposes, the Company considered the amount of time between the valuation date and the grant date to determine whether to use the latest ordinary share valuation determined pursuant to the methods described above or a straight-line calculation between the two valuation dates. The Company determined that the straight-line calculation would provide the most reasonable conclusion for the valuation of the ordinary share on these interim dates between valuations because there was no single event that occurred during these periods that resulted in the increase in fair value but rather a series of events related to exceeding the Company’s financial targets, as well as consideration of the Company’s progress toward a liquidity event.
Set forth below is a summary of the Company’s equity awards granted from January 1,
2020 to July 31, 2020, including the fair value of the underlying ordinary shares for reference:
Event
Event Date
Number of
Awards
Granted
Exercise
Price
Fair
Value per
Share for
Financial
Reporting
Third-party Valuation
December 31, 2019
—
$15.12
Option Grants
February 3, 2020
445,000
$15.49
March 31, 2020
150,000
$16.13
May 11, 2020
810,400
$18.15
June 30, 2020
$20.61
July 29, 2020
1,343,355
$23.00
Subsequent to June 30, 2020, the Company granted its Chief Executive Officer 667,595 shares of restricted share units, issuable upon the satisfaction of service and performance-based vesting conditions. As of the date of this letter, the grant is subject to the approval of the Company’s shareholders and its relevant fair value per share will be determined then. As a result, this grant has been excluded from the Company’s assessment.
March 31, 2020 valuation
The Company determined the fair value of the ordinary shares to be $16.13 per share as of March 31, 2020. During the first quarter of
2020, the Company made significant progress towards a potential initial public offering (“IPO”), including the submission of its confidential Form S-1 with the U.S. Securities and Exchange
Commission (“SEC”) on February 7, 2020 and subsequent confidential submission of its first amendment to the Form S-1 on March 26, 2020. For the Company’s valuation, three future scenarios were considered – (1) an IPO on/around [*****] (probability of [*****]), (2) an IPO on/around [*****] (probability of [*****]) and (3) remaining a private company (probability of [*****]). Due to the impact of macroeconomic factors such as the novel coronavirus pandemic on the stock market, the Company extended its IPO timeframe. As a result, the IPO date in scenario (1) was revised from [*****] as of the December 31, 2019 valuation date to [*****] as of the
March 31, 2020 valuation date, and the probability of an IPO was increased in scenario (2) between valuation dates. Both IPO scenarios derived an estimate of the Company’s equity value upon IPO using the Public Company Market Multiple
Method (“PCMMM”) approach. The remaining a private company scenario derived an estimate of the Company’s equity value using a combination of the PCMMM and the Income approach. The key assumptions used in the Company’s probability-weighted expected return method (“PWERM”) were a discount rate of 15.5% applied to all three scenarios, and the application of a discount for lack of marketability (“DLOM”) of 17.5%, 22.5% and 32.5% applied to scenarios (1), (2) and (3), respectively.
CONFIDENTIAL
TREATMENT REQUESTED BY JFROG LTD. PURSUANT TO 17 C.F.R. §200.83
June 30, 2020 valuation
The Company determined the fair value of the ordinary shares to be $20.61 per share as of June 30, 2020. Given the progression in its IPO timeline, the three scenarios were updated as follows – (1) an IPO on/around [*****] (probability of [*****]), (2) an IPO on/around [*****] (probability of [*****]) and (3) remaining a private company (probability of [*****]). The increase in the probability of an IPO in scenario (1) and the decrease in the probability of an IPO in scenario (2) were a result of the Company’s overall financial performance and the rebound of the stock market during the three months ended
June 30, 2020 compared to the three months ended March 31, 2020. Both IPO scenarios derived an estimate of the Company’s equity value upon IPO using the PCMMM approach. The remaining a private company scenario derived an estimate of the Company’s equity value using a combination of the PCMMM and the Income approach. The key assumptions used in the PWERM were a discount rate of 14.5% applied to all three scenarios, and the application of a DLOM of 10.0%, 20.0%, and 27.5%
July 29, 2020 valuation
The Company determined the fair value of the ordinary shares to be $23.00 per share as of July 29, 2020. As of the valuation date, the
Company’s IPO timeframe remained unchanged. For the Company’s valuation, three future scenarios were considered – (1) an IPO on/around [*****] (probability of [*****]), (2) an IPO on/around [*****] (probability of [*****]) and
(3) remaining a private company (probability of [*****]). The increase in the probability of an IPO in scenario (1) and the decrease in the probability of an IPO in scenario (2) were a result of the Company’s progress in its IPO preparations and continued performance of stock markets. Both IPO scenarios derived an estimate of the Company’s equity value upon IPO using the PCMMM approach. The remaining a private company scenario derived an estimate of the Company’s equity value using a combination of the PCMMM and the Income approach. The key assumptions used in the PWERM were a discount rate of 14.5% applied to all three scenarios, and the application of a DLOM of 8.0%, 19.0%, and 27.5% applied to scenarios
(1), (2) and (3), respectively. The methodology used in the March 31, 2020, June 30 2020, and July 29, 2020 valuations were applied consistently.
The Company respectfully acknowledges the Staff’s comment and advises the Staff that the weighted average exercise price per share of our share options granted subsequent to June 30, 2020 is greater than the weighted average exercise price per share of our share options granted during six months ended June 30, 2020 because our ordinary shares subsequent to June 30, 2020 were determined to have a higher valuation than valuations during the six months ended June 30, 2020. The primary reasons for the higher valuation were as follows:
• the stock market experienced significant selloffs during the second half of the first quarter of 2020 and rebounded significantly by the end of the second quarter of 2020. In addition, during the second quarter of 2020, the selected companies included in our comparable company analysis outperformed the stock market, which led to higher revenue multiples in our valuation model;
CONFIDENTIAL TREATMENT
REQUESTED BY JFROG LTD. PURSUANT TO 17 C.F.R. §200.83 decreases in the DLOM percentage applied to all three scenarios as a result of increases in the probability of an exit event in the near future as compared to previous valuations; and increases in the probability of an IPO in scenario (1) and decreases in the probability of an IPO in scenario (2) due to various factors such as the Company’s overall financial performance, the Company’s progress in its IPO preparations and the overall condition of the stock market, between valuation dates.
In order to aid the Staff’s review, the Company has set forth in the table above a summary of the Company’s equity awards granted from January 1, 2020 to July 31, 2020, including the exercise price of the underlying ordinary shares.